Copyright © Alvarius Pharmaceuticals 2021
Menu
Healing through psychedelic therapies
Alvarius is an Irish bio-pharmaceutical company researching and developing unique therapies to target addiction through the pioneering use of 5-MeO-DMT medicines.
About Us
Alvarius is an Irish bio-pharmaceutical company researching and developing unique therapies to target addiction through the pioneering use of 5-MeO-DMT medicines.
Alvarius aims to help patients overcome addictive substance-related behaviours with ground-breaking pharmaceutical solutions combined with tailored therapy. Together with our collaboration partners in University College Dublin, we are utilising the latest scientific methods to unlock the potential of psychedelics and associated therapy in treating addiction and other mental illnesses, and exploring the many associated benefits of these underused, misunderstood, and often stigmatised substances.
The therapy includes acute administration of 5-MeO-DMT coupled with expertly guided psychotherapy sessions designed to maximise the anti-addictive benefits of the psychedelic treatment.
By placing the power of recovery back in the hands of patients, our therapies can enable those suffering with stimulant addiction to retake control of their healing process.
Cutting-edge research into psychedelic treatments is reimagining the pharmaceutical approach to a wide-range of mental illnesses; Alvarius is pioneering study into the anti-addiction properties of 5-MeO-DMT and developing treatments that utilise the power of psychedelics to empower patients toward a life free from substance dependency.
We are at the precipice of harnessing the true healing potential of safe, natural psychedelics, and Alvarius is proud to be at the vanguard of establishing these incredible substances as widely used treatments in mental health.
Our Medicines
5-MeO-DMT
Often labelled ‘toad venom’ due to being naturally produced by the Sonoran Desert Toad species, the substance can also be harvested through a wide variety of plants.
Closely related to N,N-Dimethyltryptamine, better known as the psychedelic ‘DMT’, 5-MeO-DMT has a long history of use in South American shamanic rituals to enhance spiritual awareness and understanding of the self.
How it works
Our treatments aim to molecularly ‘reset’ neural pathways in the brain affected by the chronic use and abuse of addictive substances.
Our studies show that 5-MeO-DMT can normalise 75 percent of chronic cocaine-mediated protein expression changes in key, addiction-associated brain regions.
Pre-Clinical & Clinical Pipeline
Completed
- Characterisation of 5-MeO-DMT induced reversal of the detrimental effects of stimulant exposure on neural development in an in vitro 3D cerebral organoid model.
- Comparative study of the capacity of 5-MeO-DMT to other psychedelic agents in reversing the molecular changes associated with addiction and other mental illnesses
- Studies identifying the damage to human brain development caused by stimulant use, and the ability of 5-MeO-DMT to counter these detrimental effects
Ongoing
- Genomic and proteomic profiling of acute psychedelic treatment of stimulant, opioid and alcohol addiction.
- Genomic profiling of 5-Meo-DMT and other psychedelics in in vitro models of chronic stimulant, opioid and ethanol exposure utilising 3D cerebral organoids.
- Preparation for phase 1 study commencement Q1, 2022.
Upcoming
- Phase 1 of our clinical trial will examine the safety of 5-MeO-DMT in humans, while also identifying further the benefits for those living with cocaine and heroin addictions.
- Assessment of addiction-associated behavioural changes and how they can be reversed.
- Studies into 5-Meo-DMT analogues. We have a library of analogues of interest that have variant effects to those of 5-meo-DMT, that may be beneficial for different conditions also.
- Phase 2a of the clinical trial will determine the clinical efficacy of 5-Meo-DMT for patients suffering from addiction, as well as provide more safety and dosing data.
Meet the Team
Dr James Linden
C.E.O/Founder
James holds a PhD in Biochemistry from Queen’s University Belfast. With an expert knowledge of plant medicine, clinical research, and the pharmaceutical/med device industries, James successfully founded a generic drug company and a medical cannabinoid R&D company, GreenLight Pharmaceuticals Ltd. James has since built a string of over 25 investable companies in the medical R&D space over the last decade. His practical and clinical knowledge of psychedelics alongside his global research network makes him an international leader in this field.
Jan Hardorp
Director
Jan is a founding Partner at re.Mind Capital, which seeks to radically improve mental health and wellbeing through innovation. A serial entrepreneur with an eye for excellence, Jan has founded a number of successful companies in the last decade.
With an extensive knowledge in investment and portfolio management, Jan is also a trained CTI Co-Active Coach.
Dr Mike Emanuel
Director
Mike is the Founder and Managing Director of SintoPharm Pharmaceutical Consultancy. His extensive experience in the pharmaceutical industry includes a long career at Johnson & Johnson where he was Vice President of Global Clinical Operations for Europe, Middle East and Africa, leading a team of over 400 clinical research professionals in 27 countries. Mike is also a researcher at Oxford Brookes University, focussing on the history of medicine.
Professor Keith Murphy
Founder & Scientific Advisor
Keith is Professor of Neuropharmacology at University College Dublin (UCD). A former Head of Pharmacology and Head of School of Biomolecular and Biomedical Science at UCD, Keith is Principal Investigator of the UCD Neurotherapeutics Research Group.
His work examines mechanisms of synaptic plasticity to develop novel treatments for drug addiction, schizophrenia, and multiple sclerosis. Keith has several drug patents, including one for an MS treatment that is patented in the US and Europe, and is currently going into Phase II clinical study in optic neuritis.
Professor David Nutt
Scientific Advisor
David Nutt is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Sciences at Imperial College London.
A former President of the European Brain Council, the British Association of Psychopharmacology, the British Neuroscience Association, and the European College of Neuropsychopharmacology, David is currently Founding Chair of DrugScience.org.uk.
He also holds visiting Professorships at the Open University and University of Maastricht.
Daniel Robin MSc
Research & Business Development Officer
Daniel is a graduate of the Michael Smurfit Graduate Business School at University College Dublin, where his Masters degree focussed on biotechnology and business.
A former Quality Assurance Specialist with SK Biotech Ireland, Daniel has joined Alvarius Pharmaceuticals, where he will utilise his keen interest in the combination of biotechnology and psychedelic therapies for mental health disorders and will be focusing on the business development and operations of the company.
Dr Elaine Keogh
R&D Scientist
A PHD graduate of University College Dublin, Elaine is an expert in the field of animal models of addiction. Her previous work includes the pre-clinical development of a now-patented novel therapeutic for the treatment of Multiple Sclerosis, and management of client sponsored IV self-administration studies to assess abuse potential of novel drug candidates. Elaine has also worked for Abbott Diagnostics Division, where she technically managed and supported a portfolio of on-market diagnostic products.
Tanya Barakat
QA & Compliance
Tanya holds a Masters degree in Pharmaceutical Analysis from Queen’s University, Belfast. With over five years’ experience working in the chemical and pharmaceutical industry, Tanya has in recent years assisted on projects in the European cannabis industry as a Quality Assurance Advisor.
This allowed her to apply her knowledge of a highly regulated industry into a crucial emerging sector. Her areas of interest and expertise include pharmaceutical formulations, analytical chemistry, and naturally derived medicines.
Contact Us
If you have any questions or want to learn more about us, you can get in touch through the contact form below. We’d love to hear from you!
